Cancer Issues Worldwide
On 17 & 18 November, you will be able to access the European Cancer Summit 2021 virtual platform, as well as useful information and resources from the European Cancer Organisation, its Member...Read More
On 17 & 18 November, you will be able to access the European Cancer Summit 2021 virtual platform, as well as useful information and resources from the European Cancer Organisation, its Member Societies, Patient Advocacy Groups, Community 365 and Summit Supporters.
As Senior Vice President, Major Markets, Catherine is responsible for the BMS commercialization business in key...
As Senior Vice President, Major Markets, Catherine is responsible for the BMS commercialization business in key markets outside the U.S., a total of 16 countries including Japan, Germany and France, and over 4000 employees. The company portfolio of innovative prescription medicines spans therapeutic areas including Oncology, Hematology, Cardiovascular, and Immunology, with many recognizable brands including OPDIVO, REVLIMID, ELIQUIS, and ORENCIA. Previously Catherine was a senior executive at Johnson & Johnson (J&J). In her last role, she was President, Immunology at Janssen Pharmaceuticals, responsible for leading the largest single business unit within J&J. The business included 5 marketed brands, over 1000 employees, and served patients within the areas of dermatology, gastroenterology, and rheumatology. Previously, Catherine was President, Infectious Diseases where she led the U.S. commercial business in making a difference in the lives of people living with HIV. Catherine began her Johnson & Johnson career as a London-based sales representative. During her more than 25 years with J&J, she held leadership roles in Pharmaceuticals, Medical Devices and Corporate Innovation in the U.K., the U.S., and global organizations. With a passion for digital connectivity, Catherine established the first North America Pharmaceuticals Digital Governance Board and digital champions’ team at Janssen and served as Digital Governance Lead for North America. She also served as the first leader of the Janssen North America Culture Team, and in her role as Diversity & Inclusion lead for North America, Catherine built the first Employee Resource Group Council. Catherine is passionate about developing people, improving the lives of patients suffering from serious disease, and serves as a career mentor for many. In recognition of her efforts, she received the Healthcare Businesswomen’s Association Luminary award in 2018, and represented J&J at Forbes ‘NexGen’ most powerful woman in Pharma. Catherine has an Honors degree in Pharmacy from the University of Manchester and a post-graduate degree in Marketing from the University of London. She is a member of the Royal Pharmaceutical Society of Great Britain and is an Associate of the Chartered Institute of Marketing. She lives in Pennington, NJ with her husband and two teenage daughters.
Chair, World Oncology Forum and President, Foundation for the Institute of Oncology Research
Dr Hans Henri P. Kluge is the WHO Regional Director for Europe. His term began on 1 February 2020, following his...
Dr Hans Henri P. Kluge is the WHO Regional Director for Europe. His term began on 1 February 2020, following his nomination by the WHO Regional Committee for Europe and appointment by the WHO Executive Board. Throughout his career, beginning as a family doctor in Belgium, along a journey to Somalia, Liberia, the prisons in Siberia, former Soviet Union countries, Myanmar and the Democratic People’s Republic of Korea, and most recently leading the Division of Health Systems and Public Health at WHO/Europe for a decade, Dr Kluge has always been committed to achieving better health for all with a focus on the vulnerable. As Regional Director, Dr Kluge’s vision for the WHO European Region is “United action for better health”, working in partnership to achieve universal health coverage, address health emergencies and promote healthier populations. Dr Kluge is from Belgium. He is married and has two daughters.
Past-President, Union for International Cancer Control, Jordan
President of the American Society of Clinical Oncology
Matti Aapro is President (2020-2021) of the European Cancer Organisation, Member of the Board of Directors of the...
Matti Aapro is President (2020-2021) of the European Cancer Organisation, Member of the Board of Directors of the Genolier Cancer Center, Genolier, Switzerland. He received his medical degree from the Faculty of Medicine, University of Geneva, Switzerland and was a fellow at the Arizona Cancer Center in Tucson, Arizona, USA. He was the founding chair of the Medical and Radiation Therapy Department at the European Institute of Oncology in Milan. Dr Aapro is presently Executive Board member of the European School of Oncology (ESO) coordinating the activities of ESO in Arab speaking countries and in Latin America. He leads the Sharing Progress in Cancer Care (SPCC) association . He serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is Past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He is President of Honour of the French-speaking Society for Supportive Care (AFSOS), as well as Advisor to the Japanese Association for Supportive Care in Cancer (JASCC ). He has been member of the Board of the European Organization for Research and Treatment of Cancer (EORTC) and of the Board of the European Society of Medical Oncology (ESMO). Dr Aapro chaired the scientific and organizing committees of UICC’s (International Union against Cancer) World Cancer Congress of 2008 in Geneva, and 2010 in Shenzhen (China). He is a member of the ESMO Faculty and chaired the ESMO 2018 Supportive/Palliative Care track. Dr. Aapro is Honorary Editor of Critical Reviews in Oncology/Hematology, and editor of the Journal of Cancer Policy as well as Associate Editor for the geriatric section of the Oncologist. He is also founding editor of the Journal of Geriatric Oncology. He is past Associate Editor for Annals of Oncology, continuing on its editorial board, and member of several other editorial boards including ESO's CancerWorld. He has authored more than 350 publications and his major interests are new drug development, breast cancer, cancer in the elderly, and supportive care. Dr Aapro is Doctor Honoris Causa of the University of Tampere (2013) and Honorary Member of the Russian Society for Clinical Oncology (RUSSCO)(2016). He has received the 2010 Acta Oncologica Award, the 2012 ASCO B.J. Kennedy prize and the MASCC Distinguished Services Award (2016).